OncoMatch/Clinical Trials/NCT04930653
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Is NCT04930653 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mogamulizumab for folliculotropic mycosis fungoides.
Treatment: Mogamulizumab — This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, II, IIA, IIB
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: mogamulizumab (mogamulizumab)
Prior mogamulizumab
Cannot have received: systemic therapy
Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy
Cannot have received: chemotherapy
Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
Cannot have received: radiation therapy
Any radiation therapy within 21 days prior to initiating protocol therapy
Cannot have received: skin-directed therapy
Any skin-directed therapy within 14 days prior to initiating protocol therapy
Cannot have received: immunosuppressive medication
Exception: Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 daysSystemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent
Immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion
Cannot have received: live, attenuated vaccine
Live, attenuated vaccine within 30 days prior to the first dose protocol therapy
Cannot have received: stem cell transplantation
Prior stem cell transplantation
Lab requirements
Blood counts
Without bone marrow involvement: ANC >= 1,500/mm^3; Platelets >= 100,000/mm^3. With bone marrow involvement: ANC >= 1,000/mm^3; Platelets >= 75,000/mm^3
Kidney function
Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease)
Liver function
Total bilirubin <= 1.5 x ULN (unless has Gilbert's disease); AST <= 2.5 x ULN (unless has Gilbert's disease); ALT <= 2.5 x ULN (unless has Gilbert's disease)
Cardiac function
Unstable cardiac disease as defined by: cardiac events such as MI within the past 6 months; NYHA heart failure class III-IV; uncontrolled atrial fibrillation or hypertension
Total bilirubin <= 1.5 x ULN (unless has Gilbert's disease); AST <= 2.5 x ULN (unless has Gilbert's disease); ALT <= 2.5 x ULN (unless has Gilbert's disease); Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease); Without bone marrow involvement: ANC >= 1,500/mm^3; Platelets >= 100,000/mm^3. With bone marrow involvement: ANC >= 1,000/mm^3; Platelets >= 75,000/mm^3; Unstable cardiac disease as defined by: cardiac events such as MI within the past 6 months; NYHA heart failure class III-IV; uncontrolled atrial fibrillation or hypertension
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Scottsdale, Arizona
- City of Hope Medical Center · Duarte, California
- Winship Cancer Institute of Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify